Close
  Indian J Med Microbiol
 

Figure 1: Injection site sparing after subcutaneous biologics administration (a) Case 1, secukinumab, after 4 weeks, (b) Case 2, adalimumab, after 48 weeks, (c) Case 3, etanercept, after 34 weeks, and (d) Case 6, adalimumab, after 4 weeks

Figure 1: Injection site sparing after subcutaneous biologics administration (a) Case 1, secukinumab, after 4 weeks, (b) Case 2, adalimumab, after 48 weeks, (c) Case 3, etanercept, after 34 weeks, and (d) Case 6, adalimumab, after 4 weeks